Forecasting disease progression

About us

We are an AI-driven precision medicine company developing a multimodal prognostic platform to forecast disease progression in age-related disorders. Our forecasts provide new tools to physicians for improved patient care and to pharmaceutical companies for faster drug development. Our current applications are in Alzheimer's disease.

Foresight™️ - Our Predictive Platform


Our platform can leverage multiple sources of data (imaging, genetic, phenotypic, molecular and clinical variables) to better characterize individuals.

High precision targeting

We are able to rapidly and precisely target subgroups of interest in large, heterogeneous populations.

Highly actionable insights

Our digital biomarkers are highly specific and thoroughly validated, making them ready for action in any clinical setting.

To learn more, visit our Publications page!

Latest News

Perceiv AI Partners with Alleo Labs to Optimize Clinical Trials Using Advanced AI and Prognostic Biomarkers

January 8, 2024 | San Francisco, USA | Press release

Perceiv AI Achieves HIPAA Compliance, Reinforcing Commitment to Data Security and Privacy

November 28, 2023 | Montreal, Canada | Press release

New results presented at CTAD 2023 "Reducing screen failure rates due to biomarker cut-offs in early Alzheimer's disease trials using a prognostic model"

October 24, 2023 | Clinical Trials on Alzheimer's Disease conference (CTAD) | Poster

Perceiv AI Joins Johnson & Johnson Innovation–JLABS Global Network to Accelerate Precision Medicine Platform Development

June 21, 2023 | Toronto, Canada | Annoucement

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

January 17, 2023 | Boston, USA | Annoucement

Perceiv AI announces an investment of $1.5M from strategic and institutional investors to support the expansion of its prognostic platform Foresight(TM).

December 8, 2022 | Montréal, Canada | Press release

Perceiv AI today announced the closing of an investment of $1.5M. Perceiv AI is a precision medicine company optimizing and de-risking clinical trials and enabling physicians to make a timely diagnosis of degenerative brain disorders by forecasting disease evolution.

The round was composed of strategic and institutional investors from Canada and the US, including CABHI (Centre for Aging + Brain Health Innovation), Plug and Play Ventures, Boreal Ventures, IKJ Capital, Red Abbey Labs, Investissement Québec, as a representative of the government of Quebec, as well as angel investors. "We are very excited to move forward to the next phase of our growth with the support of these strategically important investors," said Dr. Christian Dansereau, CEO of Perceiv AI.

The funds will be used to expand the Foresight platform, Perceiv AI's proprietary AI/ML-driven prognostic platform that predicts disease progression. The company aims to add other key resources by bringing additional talent to the team to advance its commercial and scientific activities and strengthen its regulatory effort.

Perceiv AI Leverages Big Data and Artificial Intelligence to Predict Disease Progression and Make Clinical Trials More Effective

December 2, 2022 | Montréal, Canada | Press release

Find all our past news and announcements in our Newsroom!

Meet our Team

Christian Dansereau, Ph.D.

CEO & Founder


César Laurent, Ph.D.

CTO & Founder


Angela Tam, Ph.D.

Senior Scientist


Adrián Noriega de la Colina, M.D., Ph.D.

Clinical and Regulatory Lead


Maxime Jacques, M.A.Sc

Software Engineer

Christine Newton, C.P.A.

VP Finance

Meet our Advisors

Yoshua Bengio, Ph.D.

Full Professor at Université de Montréal,

Founder and Scientific Director of Mila,

Scientific Director of IVADO


Serge Gauthier, M.D.

Full Professor at McGill University,

Director of the Alzheimer Disease and Related Disorders Research Unit, Douglas Research Centre


Richard H. Stark, M.S.

Physicist, Entrepreneur & Investor Former Executive at Varian, ViewRay and Elekta


Betsabeh Madani Hermann, M.B.A.

Healthcare executive & investor,

VP strategy and BD



Partners & Collaborators

CCNA - Canadian Consortium on Neurodegeneration in Aging
Acasti Pharma Inc.
vTv Therapeutics Inc.
Montreal Heart Institute - Institut de Cardiologie de Montréal
DalCor Pharmaceuticals
McGill University

Supported by

Mila - Quebec AI Institute
CQDM - Consortium de recherche biopharmaceutique
CLSI - California Life Sciences Institute
CTA - Canadian Technology Accelerators
CTS - Campus des Technologies de la Santé
District 3 Innovation Hub